Cue Biopharma, Inc.
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company developing injectable therapeutics to selectively engage and modulate disease-specific T cells for autoimmune, inflammatory and cancer indications. Its Immuno-STAT platform underlies programs designed to restore immune balance, including… From the company’s description.
Over the twelve months to Jun 30, 2026, Cue Biopharma, Inc. reported revenue of $37.66M, up 354.4% from a year earlier, and a net loss of $164.11M. Its operating margin was −262.0%, and operations used $50.05M in cash. In fiscal 2025, it reported revenue of $27.47M, up 195.7% from fiscal 2024, and a net loss of $26.60M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cue Biopharma, Inc. does
In the company’s own words
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company developing injectable therapeutics to selectively engage and modulate disease-specific T cells for autoimmune, inflammatory and cancer indications. Its Immuno-STAT platform underlies programs designed to restore immune balance, including CUE-401, a preclinical candidate for autoimmune disease, and the CUE-500 series, which targets pathogenic cells such as autoreactive B cells. Cue is prioritizing CUE-401 development; CUE-501 is licensed to Boehringer Ingelheim, while its CUE-100 oncology candidates, including CUE-101 and CUE-102, are licensed to ImmunoScape. The company has no commercial products and focuses its activities on research and development, using external collaborators for development of licensed programs. It previously licensed CUE-401 to Ono Pharmaceutical and regained worldwide rights in 2025; it also regained CUE-101 rights in the LG Chem territory that year. Its website is https://www.cuebiopharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOMERVILLE, MA
- Fiscal year end
- December
- CIK
- 1645460
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cue Biopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cue Biopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cue Biopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cue Biopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cue Biopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”